Market Spotlight: Eating Disorders

Figure 1: Trends in worldwide prevalent cases of eating disorders in females aged 10–19 years, 2017–26
Figure 2: Overview of pipeline drugs for eating disorders in the US
Figure 3: Pipeline drugs for eating disorders, by company
Figure 4: Pipeline drugs for eating disorders, by drug type
Figure 5: Pipeline drugs for eating disorders, by classification
Figure 6: Probability of success in the eating disorders pipeline
Figure 7: Clinical trials in eating disorders
Figure 8: Top 10 drugs for clinical trials in eating disorders
Figure 9: Top 10 companies for clinical trials in eating disorders
Figure 10: Trial locations in eating disorders
Figure 11: Eating disorders trials status
Figure 12: Eating disorders trials sponsors, by phase

Table 1: Worldwide prevalent cases of eating disorders in females aged 10–19 years, 2017–26
Table 2: Prevalent cases of eating disorders in females aged 10–19 years in Africa, 2017–26
Table 3: Prevalent cases of eating disorders in females aged 10–19 years in Asia, 2017–26
Table 4: Prevalent cases of eating disorders in children aged 10–19 years in Latin America and the Caribbean, 2017–26
Table 5: Prevalent cases of eating disorders in children aged 10–19 years in Northern America, 2017–26
Table 6: Prevalent cases of eating disorders in children aged 10–19 years in Oceania, 2017–26
Table 7: Prevalent cases of eating disorders in all ages in Europe, 2017–26
Table 8: Marketed drugs for eating disorders
Table 9: Pipeline drugs for eating disorders in the US
Table 10: Historical global sales, by drug ($m), 2016–20
Table 11: Forecasted global sales, by drug ($m), 2021–25